If you’re one of the millions of Americans currently taking a GLP-1 drug like semaglutide (Ozempic and Wegovy), listen up: The Food and Drug Administration is officially warning users about a rare but serious vision-robbing condition linked to the products.

On Monday, the FDA stated that semaglutide and other GLP-1s on the market carry a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The agency is now mandating that all GLP-1 makers add a warning disclosing this risk to their labeling. Though both doctors and patients should be aware of the possible side effect, NAION appears to be a rare complication of GLP-1 use, the FDA says.

The NAION connection

NAION is caused by decreased or stopped blood flow to the optic nerve, which can then lead to sudden and painless vision loss in the eye.…